TY - JOUR
T1 - Poly(ADP-ribose)
T2 - A Dynamic Trigger for Biomolecular Condensate Formation
AU - Leung, Anthony K.L.
N1 - Funding Information:
I thank Dr Phillip A. Sharp and members of my laboratory for critical comments on this manuscript and Morgan Dasovich for help in making the figures. Our work on ADP-ribosylation is supported by a Johns Hopkins Discovery Award, Research Scholar Award ( RSG-16-062-01-RMC ) from the American Cancer Society , and R01GM104135 from the National Institutes of Health . I sincerely apologize to all authors whose excellent contributions to the field could not be individually cited owing to space limitations.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/5
Y1 - 2020/5
N2 - Poly(ADP-ribose) (PAR) is a nucleic acid-like protein modification that can seed the formation of microscopically visible cellular compartments that lack enveloping membranes, recently termed biomolecular condensates. These PAR-mediated condensates are linked to cancer, viral infection, and neurodegeneration. Recent data have shown the therapeutic potential of modulating PAR conjugation (PARylation): PAR polymerase (PARP) inhibitors can modulate the formation and dynamics of these condensates as well as the trafficking of their components – many of which are key disease factors. However, the way in which PARylation facilitates these functions remains unclear, partly because of our lack of understanding of the fundamental parameters of intracellular PARylation, including the sites that are conjugated, PAR chain length and structure, and the physicochemical properties of the conjugates. This review first introduces the role of PARylation in regulating biomolecular condensates, followed by discussion of current knowledge gaps, potential solutions, and therapeutic applications.
AB - Poly(ADP-ribose) (PAR) is a nucleic acid-like protein modification that can seed the formation of microscopically visible cellular compartments that lack enveloping membranes, recently termed biomolecular condensates. These PAR-mediated condensates are linked to cancer, viral infection, and neurodegeneration. Recent data have shown the therapeutic potential of modulating PAR conjugation (PARylation): PAR polymerase (PARP) inhibitors can modulate the formation and dynamics of these condensates as well as the trafficking of their components – many of which are key disease factors. However, the way in which PARylation facilitates these functions remains unclear, partly because of our lack of understanding of the fundamental parameters of intracellular PARylation, including the sites that are conjugated, PAR chain length and structure, and the physicochemical properties of the conjugates. This review first introduces the role of PARylation in regulating biomolecular condensates, followed by discussion of current knowledge gaps, potential solutions, and therapeutic applications.
KW - ADP-ribosylation
KW - biomolecular condensate
KW - liquid–liquid phase separation
KW - poly(ADP-ribose)
KW - poly(ADP-ribose) polymerase
KW - poly(ADP-ribose) polymerase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=85079846415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079846415&partnerID=8YFLogxK
U2 - 10.1016/j.tcb.2020.02.002
DO - 10.1016/j.tcb.2020.02.002
M3 - Review article
C2 - 32302549
AN - SCOPUS:85079846415
SN - 0962-8924
VL - 30
SP - 370
EP - 383
JO - Trends in Cell Biology
JF - Trends in Cell Biology
IS - 5
ER -